Pureos Bioventures
Investor profile
Venture capital
Deals
9
distinct rounds
Companies
8
backed
Active span
2018–2024
7 yrs
Total round €
€206M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Adjuvant Capital2
- Redalpine2
- Schroders Capital2
- 4BIO Capital1
- BioGeneration Ventures1
- BioMedPartners1
- BOM1
- btov Partners1
- Citryll’s founders1
- Curie Capital1
- Forbion1
- Fresenius Medical Care Ventures1
- GF Group Holding1
- IDInvest Partners1
- Industrifonden1
- Institute for Follicular Lymphoma Innovation1
- Johnson & Johnson1
- Kurma Partners1
- LF Investment1
- Neurimmune Holding1
- Novartis Venture Fund1
- Novo Holdings1
- Repair Impact Fund1
- Sanofi Ventures1
- Seventure Partners1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Citryll | Netherlands | 1 | €85M |
| Araris Biotech | Switzerland | 2 | €38M |
| Memo Therapeutics | Switzerland | 1 | €26M |
| MinervaX | Denmark | 1 | €22M |
| Engimmune Therapeutics | Switzerland | 1 | €15M |
| Alentis Therapeutics | Switzerland | 1 | €11M |
| NovaGo Therapeutics | Switzerland | 1 | €8.6M |
| Corlieve Therapeutics | France | 1 | €0 |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Citryll | Series B | €85M | 2024-12 |
| Memo Therapeutics | Series C | €26M | 2023-11 |
| Araris Biotech | Other | €24M | 2022-10 |
| MinervaX | Other | €22M | 2022-12 |
| Engimmune Therapeutics | Seed | €15M | 2022-05 |
| Araris Biotech | Seed | €14M | 2020-10 |
| Alentis Therapeutics | Series A | €11M | 2019-03 |
| NovaGo Therapeutics | Series A | €8.6M | 2018-12 |
| Corlieve Therapeutics | Seed | €0 | 2020-11 |